2013

Musialek P, Tekieli L, Kostkiewicz M, Klimeczek P, Miszalski-Jamka T, Mazur W, Azot W, Majka M, Wojakowski W, Banys RP, Jarocha D, Walter Z, Pieniazek P, Olszowska M, Zmudka K, Pasowicz M, Kereiakes DJ, Podolec P, Tracz W.  Myocardial infarct size determines early uptake of autologous CD34+ cells: Evidence from late gadolinium-enhanced myocardial imaging integrated with ^99mTc-extametazime-labeled cells visualization in humans. Circ Cardiovascular Imaging 2013;6:320-328.

Lee PV; compiled by Morton Kern from the comments of: Rao SV, Bell M, Ragosta M, Welt F, Ohman EM, Uretsky B, De Bruyne B, Garratt KN, Rosenfield K, Turi Z, Bass TA, Tommaso C, Mintz GS, Vetrovec G, Krucoff MW, Yeung AC, Kereiakes DJ, Klein LW, Weiner B, Stone GW, Samady H, Applegate R, Bailey S, Bach R, Jeremias A, Pichard A, Morrison D.  Conversation in cardiology: Should FFR and IVUS be counted as PCI? Catheter Cardiovascular Interv 2013; Feb 13 [Epub ahead of print].

Kandzari DE, Teirstein PS, Kereiakes DJ, Cannon LA, Hearne SE, Kuo HC, Ying SW, Cheong WF, Popma JJ.  Procedural effectiveness of a novel 1.20mm diameter angioplasty catheter: clinical and angiographic outcomes. J Interv Cardiol 2013;26:131-136.

Forrest JK, Lansky AJ, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, Skelding KA, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, Stone GW. Evaluation of XIENCE V everolimus-eluting and TAXUS EXPRESS2 paclitaxel-eluting coronary stents in patients with jailed side branches from the SPIRIT IV trial at 2 years. Am J Cardiol 2013;Mar 14 [Epub ahead of print].

2012

Cannon LA, Kereiakes DJ, Mann T, Popma JJ, Mooney MR, Mishkel GJ, Lee TC, Wilson BH, Stuckey TD, Orlow S, McGarry T, Ring ME, Kellett MA, Underwood P, Dawkins KD. TAXUS PERSEUS Small Vessel:  A Prospective Evaluation in a non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels.  EuroIntervention 2011;6:920-7.

McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin Type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-53

Kereiakes DJ, Popma JJ, Cannon LA, Kandzari DE, Kimmelstiel CD, Meredith IT, Teirstein PS, Verheye S, Allocco DJ, Dawkins KD, Stone W. Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomized controlled clinical trials. Eurointervenion 2012;8:187-95

Pervaiz MH, Sood P, Sudhir K, Hermiller JB, Hou L, Hattori K, Su X, Cao S, Wang J, Applegate RJ, Kereiakes DJ, Yaqub M, Stone GW, Cutlip DE.  Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. Circ Cardiovasc Interv. 2012;5:150-156

Kereiakes DJ, Chrysant SG, Izzo JL Jr, Littlejohn T 3rd, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R.  Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. J Clin Hypertens 2012;14:149-157

Marso SP, Teirsein PS, Kereiakes DJ, Moses J, Lasala J, Grantham JA.  Percutaneous coronary intervention use in the United States: defining measures of appropriateness. JACC Cardiovasc Interv 2012;5:229-235

Chrysant SG, Izzo JL Jr, Kereiakes DJ, Littlejohn T 3rd, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R.  Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J Am Soc Hypertens 2012;6:132-141

Miszalski-Jamka T, Klimeczek P, Banys R, Krupinski M, Nycz K, Bury K, Lada M, Pelberg R, Kereiakes DJ, Mazur W. The composition and extent of coronary artery plaque detected by multislice computed tomographic angiography provides incremental prognostic value in patients with suspected coronary artery disease. Int J Cardiovasc Imaging 2012;28:621-31 (Mar).

Sarembock IJ , Kereiakes DJ. Risk stratification and timing of revascularization: Which patients benefit from early versus later revascularization? Curr Cardiol Rep 2012;14:510-520

Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes DJ, Sangiorgi D, Bacchi Reggiani L, Kaiser C, Kim HS, De Waha A, Ribichini F, Stone GW. Stent thrombosis with everolimus-eluting stents: Meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012;5:357-364

Mazzaferri EL, Kereiakes DJ. The truth and consequences of the C-PORT E trial. Cardiology Today Intervention 2012;1:6-9

Chysant SG, Izzo J, Kereiakes DJ, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY study. Am J Cardiovasc Drugs 2012;12:233-43

O'Brien TM , Menon S, Stephens T, Mazur W, Chung ES. Algorithm-based assessment of target weight removal in acute decompensated heart failure. Congest Heart Fail. 2012;18:43-6.

Mazur W , Hor KN, Germann JT, Fleck RJ, Al-Khalidi HR, Wansapura JP, Chung ES, Taylor MD, Jefferies JL, Benson DW, Gottliebson WM. Patters of left ventricular remodeling in patients with Duchenne muscular dystrophy: a cardiac MRI study of ventricular geomeetry, global function, and strain. Int J Cardiovasc Imaging 2012;28:99-107.

Chung ES , Dye L, Feldmann A, Conley D, Bartone C, McDonald M. Effect of automated, point of care electronic medical record screening for appropriate implantable device use in heart failure patients. Am J Med Qual 2012;27:524-528.

Miszalski-Jamka T, Szczeklik W, Nycz K, Sokolowska B, Bury K, Zawadowski G, Noelting J, Mazur W, Musial J. The mechanics of left ventricular dysfunction in patients with Churg-Strauss syndrome. Echocardiography 2012;29:568-78.

Srivatsa SS, Taylor MD, Hor K, Collins DA, King-Strunk M, Pelberg R, Mazur W.  Liquefaction necrosis of mitral annular calcification (LNMAC):  review of pathology, prevalence, imaging and management: proposed diagnostic imaging criteria with detailed multi-modality and MRI image characterization. Int J Cardiovasc Imaging 2012;28:1161-71.

Galkina EV, Butcher M, Keller SR, Goff M, Bruce A, Pei H, Sarembock IJ, Sanders JM, Nagelin MH, Srinivasan S, Kulkarni RN, Hedrick CC, Lattanzio FA, Dobrian AD, Nadler JL, Ley K. Accelerated atherosclerosis in Apoe-/ - mice heterozygous for the insulin receptor and the insulin receptor substrate-1. Arterioscler Thromb Vasc Biol. 2012;32:247-256.

Krupinski M, Miszalski-Jamka T, Guzik B, Andres M, Zmudka K, Mazur W, Pelberg R, Banys R, Urbanczyk M, Kostkiewicz M. Computed tomography coronary angiography demonstrate high correlation for area stenosis quantification in noncalcified and mixed plaques.  Clin Imaging. 2012;36:724-731.

Henry-Okafor Q, Collins SP, Jenkins CA, Miller KF, Maron DJ, Naftilan AJ, Weintraub N, Fermann GJ, McPherson J, Menon S, Sawyer DB, Storrow AB.  Soluble ST2 as a diagnostic and prognostic marker for acute heart failure syndromes.  Open Biomark J. 2012;5:1-8.

 

2011

Cannon LA, Kereiakes DJ, Mann T, Popma JJ, Mooney MR, Mishkel GJ, Lee TC, Wilson BH, Stuckey TD, Orlow S, McGarry T, Ring ME, Kellett MA, Underwood P, Dawkins KD. TAXUS PERSEUS Small Vessel:  A Prospective Evaluation in a non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels.  EuroIntervention 2011;6:920-7.

Quyyumi AA, Waller EK, Murrow J, Esteves F, Galt J, Oshinski J, Lerakis S, Sher S, Vaughan D, Perin E, Willerson J, Kereiakes DJ, Gersh BJ, Gregory D, Werner A, Moss T, Chan WS, Preti R, Percora AL. CD34+ cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent.  Am Heart J 2011;161:98-105.

Tantry U, Kereiakes DJ, Gurbel P. Clopidogrel and proton pump inhibitors:  Influence of pharmacologic interactions on clinical outcomes and mechanistic explanations.  J Am Coll Cardiol Interventions 2011; 4:365-380.

Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, Kereiakes DJ for the SPIRIT IV investigators.  Randomized comparison of everolimus- and paclitaxel-eluting stents:  Two-year follow-up from the SPIRIT IV (Clinical evaluation of the XIENCE V everolimus eluting coronary stent system) trial. J Am Coll. Cardiol. 2011;58:19-25.

Kereiakes DJ, Smits PC, Kedhi E, Parise H, Fahy M, Serruys PW, Stone GW.  Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment:  Pooled analysis from the SPIRIT II, III, IV and COMPARE trials. EuroIntervention 2011;7:74-83.

Neutel J, Kereiakes DJ, Stoakes KA, Maa JF, Shojaee A, Waverczak WF. Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (=65 years) stratified by age, gender, and race. Drugs Aging 2011;28:477-90.

The TENACITY steering committee and investigators.  A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement:  The Tirofiban Evaluation of Novel dosing versus Abciximab with Clopidogrel and Inhibition of Thrombin StudY (TENACITY) study trial.  Catheter Cardiovasc Interv 2010 Nov 8 [Epub]

Kereiakes DJ, Neutel JM.  Seated cuff blood pressure-lowering efficacy of an olmesartan medoximil-based treatment regimen in patients with type 2 diabetes mellitus.  Drugs in Research & Development 2011;11: 251-7. (Sept)

Miszalski-Jamka T, Szczeklik W, Sokolowska B, Miszalki-Jamka K, Karway K, Grzadziel G, Mazur W, Kereiakes DJ, Musial J. Cardiac involvement in Wegener’s granulomatosis resistant to induction therapy. Eur Radiol 2011; 21:2297-3054 (Nov).

Kereiakes DJ. Novel drug-eluting coronary stents nearing approval in the United States. Cardiac Interventions Today 2011;5:29-34 (Aug).

Stone GW, Kedhi E, Kereiakes DJ, Parise H, Fahy M, Serruys PW, Smits PC.  Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011;124:893-900 (Aug).

Tantry US, Kereiakes DJ, Gurbel PA. Role of ticagrelor in the treatment of coronary artery disease. Clinical Investigation 2011;1:429-437.

Cannon LA, Jones J, Cheong WF, Kusano H, Kereiakes DJ, Wang J, Zhang Z, Li X, Hattori K, Sood P, Simon D, Costa MA. The XIENCE nano^™ everolimus eluting coronary stent system for the treatment of small coronary arteries: The SPIRIT small vessel trial. Catheterization and Cardiovascular Interventions 2011 Nov 25 [Epub]; doi:10.1002/ccd.23397.

Pires LA, Ghio S, Chung ES, Tavazzi L, Abraham WT, Gerritse B.  Relationship between acute improvement in left ventricular function to 6-month outcomes after cardiac resynchronization therapy in patients with chronic heart failure. Congest Heart Fail 2011;17:65-70.

Hor KN, Baumann R, Pedrizzetti G, Tonti F, Gottliebson WM, Taylor M, Benson W, Mazur W.  Magnetic resonance derived myocardial strain assessment using feature tracking.  J Vis Exp. 2011;48:2356.

Pelberg R, Budoff M, Goraya T, Keevil J, Lesser J, Litwin S, Newton C, Ridner M, Rumberger J, Teague S, Winkler M.  Training, competency, and certification in cardiac CT: A summary statement from the Society of Cardiovascular Computed Tomography.  Journal of Cardiovascular Computed Tomography 2011;5:279-285.

Egnaczyk G, Milano CA, Rogers JG.  Clinical trials in mechanical circulatory support.  Heart Failure Clinics 2011;7:457-66.

Kereiakes DJ, Neutel JM.  Seated cuff blood pressure-lowering efficacy of an olmesartan medoximil-based treatment regimen in patients with type 2 diabetes mellitus.  Drugs in Research & Development 2011:11;251-7. (Sept)

Miszalski-Jamka T, Szczeklik W, Sokolowska B, Miszalki-Jamka K, Karway K, Grzadziel G, Mazur W, Kereiakes DJ, Musial J. Cardiac involvement in Wegener’s granulomatosis resistant to induction therapy. Eur Radiol 2011; 21:2297-3054 (Nov).

Kereiakes DJ. Novel drug-eluting coronary stents nearing approval in the United States. Cardiac Interventions Today 2011;5:29-34 (Aug).

Stone GW, Kedhi E, Kereiakes DJ, Parise H, Fahy M, Serruys PW, Smits PC.  Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011;124:893-900 (Aug).

Kereiakes DJ, Cannon LA, Ormiston JA, Turco MA, Wang H, Underwood P, Dawkins KD.  Propensity-matched patient level comparison of the TAXUS Liberté and TAXUS Element (ION) paclitaxel-eluting stents.  Am J Cardiol 2011;108:828-37 (Sept)

Murrow J, Esteves F, Galt J, Chen J, Garcia E, Lin J. Lerakis S, Sher S, Khan Pohlel F, Waller EK, Vaughan D, Perin E, Willerson J, Kereiakes DJ, Preti R, Percora AL, Quyyumi AA.  Characterization of mechanical dyssychrony measured by gated photon emission computed tomography phase analysis after acute ST-elevation myocardial infarction.  J Nucl Cardiol 2011;18:912-9. (Oct)

Povsic TJ, O’Connor CM, Henry T, Taussig A, Kereiakes DJ, Fortuin FD, Niederman A, Schatz R, Spencer III R, Owens D, Banks M, Joseph D, Roberts R, Alexander JH, Sherman W.  A double-blind, randomized controlled multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure following myocardial infarction.  Am Heart J 2011;162:654-662.e1. (Oct)

Planer D, Smits PC, Kereiakes DJ, Kedhi E, Fahy M, Xu K, Serruys PW, Stone GW.  Comparison of everolimus-eluting and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results of the SPIRIT and COMPARE trials. J Am Coll Cardiol Intv 2011;4:1104-15. (Oct)

Izzo JL Jr, Chrysant SG, Kereiakes DJ, Littlejohn III T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. 24-hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. J Clin Hypertens 2011;13:873-80. (Dec)

Claessen B, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW.  Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus-eluting vs. paclitaxel-eluting stents:  Pooled analysis from the  SPIRIT and COMPARE randomized trials.  J Am Coll Cardiol Intv 2011;4:1209-15. (Dec)

Mega JL, Hochholzer W, Frelinger III AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. J Am Med Assn 2011;306:2221-8.

O’Brien TM, Menon S, Stephens T, Mazur W, Chung ES. Algorithm-based assessment of target weight removal in acute decompensated heart failure. Congestive Heart Failure 2011 [online 9/13/11 before print]; doi:10.1111/j.1751-7133.2011.00251.x

Pelberg R, Budoff M, Goraya T, Keevil J, Lesser J, Litwin S, Newton C, Ridner M, Rumberger J, Teague S, Winkler M.  Training, competency, and certification in cardiac CT: A summary statement from the Society of Cardiovascular Computed Tomography.  Journal of Cardiovascular Computed Tomography 2011;5:279-285.

Aronson D, Verbalis JG, Mueller M, Krum H; on behalf of the DILIPO investigators.  Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Eur J Heart Fail. 2011 Jan 3.

Pires PA, MD, Ghio S, Chung ES, Tavazzi L, Abraham WT, Gerritse B.  Relationship between acute improvement in left ventricular function to six-month outcomes after cardiac resynchronization therapy. Congestive Heart Fail. 2011; 17: 64-69.

Mazur W, Hor KN, Germann JT, Fleck RJ, Al-Khalidi HR, Wansapura JP, Chung ES, Taylor MD, Jefferies JL, Woodrow Benson D, Gottliebson WM. Patterns of left ventricular remodeling in patients with Duchenne Muscular Dystrophy: a cardiac MRI study of ventricular geometry, global function, and strain. Int J Cardiovasc Imaging. 2011 Jan 8.

Hor KN, Wansapura JP, Al-Khalidi HR, Gottliebson WM, Taylor MD, Czosek RJ, Nagueh SF, Akula N, Chung ES, Benson WD, Mazur W. Presence of mechanical dyssynchrony in Duchenne muscular dystrophy. J Cardiovasc Magn Reson. 2011 Feb 2;13:12.

Bhatti S, Hakeem A, Yousuf MA, Al-Khalidi HR, Mazur W, Shizukuda Y. Diagnostic performance of computed tomography angiography for differentiating ischemic vs nonischemic cardiomyopathy. J Nucl Cardiol. 2011 May;18(3):407-20.

Szczeklik W, Miszalski-Jamka T, Mastalerz L, Sokolowska B, Dropinski J, Banys R, Hor KN, Mazur W, Musial J. Multimodality assessment of cardiac involvement in Churg-Strauss syndrome patients in clinical remission. Circ J. 2011ar;75(3):649-55.

Hor KN, Mazur W, Taylor MD, Al-Khalidi HR, Cripe LH, Jefferies JL, Raman SV, Chung ES, Kinnett KJ, Williams K, Gottliebson WM, Benson DW. Effects of steroids and angiotensin converig enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectiona and longitudinal study uilizing cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2011;13:60-67.

Szczeklik W, Miszalski-Jamka T, Mastalerz L, Sokolowska B, Dropinski J, Banys R, Hor KN, Mazur W, Musial J. Multimodality assessment of cardiac involvement in Churg-Strauss Syndrome patients in clinical remission. Circ J. 2011;75:649-55.

Srivatsa SS, Taylor MD, Hor KN, Collins DA, King-Strunk M, Pelberg RA, Mazur W. Liquefaction necrosis of mitral annular calcification (LNMAC): review of pathology, prevalence, imaging and management: proposed diagnostic imaging criteria with detailed multi-modality and MRI image characterization. Int J Cardiovasc Imaging 2011; Aug 24 [Epub].

Pelberg R , Budoff M, Goraya T, Keevil J, Lesser J, Litwin S, Newton C, Ridner M, Rumberger J, Teague S, Winkler M. Training, competency, and certification in cardiac CT: a summary statement from the Society of Cardiovascular Computed Tomography. Journal of Cardiovascular Computed Tomography 2011;5:279-285.

Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venkitachlam L, Tsapatsaris NP, Piemonte TC, LagoRM, Rutter MK, Nesto RW for Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Th prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care 2011;34:464-467.

Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ for Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a Phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011;124:304-313.

2010

Kereiakes DJ. Cultivating prognosis following percutaneous coronary intervention: The American College of Cardiology/National Cardiovascular Data Registry (ACC/NCDR) risk score. J Am Coll Cardiol 2010;55:1933-5.

Naidu SS, Turco MA, Mauri L, Coolong A, Popma JJ, Kereiakes DJ. Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy). Am J Cardiol 2010; 105:1060-1064.

Kereiakes DJ, Maa JF, Shojaee A, Dubiel R. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study. Am J Cardiovasc Drugs 2010;10:239-46.

Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom J, Safe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel non-responders and responders and the effect of switching therapies: The RESPOND study. Circulation 2010;121:1188-1199.

Gurbel P, Tantry U, Kereiakes DJ. Interaction between clopidogrel and proton pump inhibitors and management strategies in patients with cardiovascular diseases.  Drug, Healthcare and Patient Safety 2010;2:223-240.

Gurbel PA, Kereiakes DJ, Tantry US. Ticagrelor for the treatment of arterial thrombosis. Expert Opin. Pharmacother. 2010;11:2251-2259.

Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes DJ, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.  J Am Coll Cardiol 2010; 56:919-33.

Kereiakes DJ, Cannon LA, Feldman RL, Popma JJ, Magorien R, Whitbourn R, Dauber IM, Rabinowitz AC, Ball MW, Bertolet B, Kabour A, Foster MC, Wang JC, Underwood P, Dawkins KD. Clinical and angiographic outcomes following treatment of de novo coronary stenoses with a novel platinum-chromium thin strut stent: primary results of the PERSEUS (a Prospective Evaluation in a Randomized trial of the Safety and Efficacy of the Use of the TAXUS Element paclitaxel-eluting coronary Stent system) trial. J Am Coll Cardiol 2010; 56:264-71.

Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping: One piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol 2010;56:112-6.

Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, Simonton CA, Sudhir K, Stone GW.  Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: Results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol 2010;56:2084-9.

Miszalski-Jamka T, Klimeczek P, Tomala M, Krupinski M, Zawadowski G, Noelting J, Lada M, Sip K, Banys R, Mazur W, Kereiakes DJ, Zmudka K, Pasowicz M.  Extent of RV dysfunction and myocardial infarction assessed by CMR are independent outcome predictors early after STEMI treated with primary angioplasty.  JACC Imaging 2010;3:1237-46.

Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ for the SPIRIT IV investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. New Engl J Med 2010;362:1663-74.

Punzi H, Neutel J, Kereiakes DJ, Shojaee A, Waverczak W, Dubiel R, Maa JF. Efficacy of amlodipine and Olmesartan Medoxomil in Patients with Hypertension: The AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis 2010;4:209-221.

Kereiakes DJ, Neutel J. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes:  analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring. Ther Adv Cardiovasc Dis 2010;4:285-93.

Allocco D, Cannon L, Britt A, Dawkins K, Heil J, Nersesov A, Wehrenberg S, Kereiakes DJ. A Prospective Evaluation of the Safety and Efficacy of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions: Design and Statistical Methods of the PERSEUS Clinical Program. Trials 2010;11:1-15.

Anand IS, Deswal A, Kereiakes DJ, Purkayastha D, Zappe DH. Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure: the DESTINY-HF trial. Vasc Health and Risk Mgmt 2010;6:449-455.

Kereiakes DJ. ST segment elevation myocardial infarction: Medication protocols for interhospital transfer. J Invas Cardiol 2010;22:4B-9B 

Neutel JM, Kereiakes DJ, Waverczak WF, Stoakes KA, Xu J, Shoejaee A. Effects of an olmesartan medoxomil-based treatment algorithm on 24 hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin. 2010;26:721-8.

Holmes DR, Jr., Kereiakes DJ, Garg S, Serruys PW, Dehmer GJ, Ellis SG, Williams DO, Kimura T, Moliterno DJ. Stent thrombosis. J Am Coll Cardiol 2010;56:1357-65.

Neutel JM, Kereiakes DJ on behalf of the BENEFICIARY investigators. An Olmesartan Medoxomil-based treatment algorithm is effective in achieving 24-hour blood pressure control in patients with Type 2 diabetes, regardless of age, race, gender, or severity of hypertension: subgroup analysis of the BENEFICIARY study. Am J of Cardiovasc Drugs 2010;10:289-303.

Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip  DE, Pencina M, Massaro JM. Rationale and design of the Dual Antiplatelet Therapy study, a prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of a 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:1035-1041.e.1.

Kereiakes DJ, Sudhir K, Hermiller JB, Gordon PC, Ferguson J, Yaqub M, Sood P, Su X, Yakubov S, Lansky A, Stone GW.  Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: The SPIRIT III (A Clinical Evalutation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. J Am Coll Cardiol Intv 2010;3:1229-39.

Kereiakes DJ. Safety of drug-eluting stents. Rev Cardiovasc Med 2010;11:186-200.

Mortensen PT, Herre JM, Chung ES, Bax JJ, Gerritse B,  Kruijshoop M,  Murillo J. The effect of left ventricular pacing site on cardiac resynchronization therapy outcome and mortality: The results of a PROSPECT sub-study. Europace. 2010;12:1750-1756.

Chung ES, Menon S, Bartone L, Akula N, Wagner J. Ultrafiltration in Heart Failure Patients with Preserved Systolic Function. J. Am. Coll. Cardiol., March 9, 2010;55:A26.E244.

Hagenbuch SC, Gottliebson WM, Wansapura J, Mazur W, Fleck R, Benson DW, Hor KN. Detection of progressive cardiac dysfunction by serial evaluation of circumferential strain in patients with Duchenne muscular dystrophy. Am J Cardiol. 2010 May 15;105(10):1451-5.

Chung ES, Mazur W. Echocardiographic assessment of dyssynchrony: moving forward. Circ Heart Fail. 2010 Sep 1;3(5):561-4.

Chung ES, Dan D, Solomon SD, Bank AJ, Pastore J, Iyer A, Berger RD, Franklin JO, Jones G, Machado C, Stolen CM. Effect of peri-infarct pacing early after myocardial infarction: results of the prevention of myocardial enlargement and dilatation post myocardial infarction study. Circ Heart Fail. 2010 Nov 1;3(6):650-8.

van Bommel RJ, Gorcsan J 3rd, Chung ES, Abraham WT, Gjestvang FT, Leclercq C, Monaghan MJ, Nihoyannopoulos P, Peraldo C, Yu CM, Demas M, Gerritse B, Bax JJ. Effects of cardiac resynchronization therapy in patients with heart failure having a narrow QRS Complex enrolled in PROSPECT. Heart. 2010 Jul;96(14):1107-13.

Hor KN, Gottliebson W, Carson C, Wash E, Cnota J, Fleck R, Wansapura J, Klimeczek P, Al-Khalidi HR, Chung ES, Benson DW Mazur W. Comparison of Magnetic Resonance Feature Tracking for Strain Calculation With Harmonic Phase Imaging Analysis. J. Am. Coll. Cardiol. Img., February 2010;3:144-151.

Chan PS,  Khumri T, Chung ES, Ghio S, Reid KJ, Gerritse B, Nallamothu BK, and Spertus JA. Echocardiographic Dyssynchrony and Health Status Outcomes From Cardiac Resynchronization Therapy: Insights From the PROSPECT Trial. J. Am. Coll. Cardiol. Img., May 2010;3:451-460.

Chung ES , Katra RP, Ghio S, Bax J, Gerritse B, Hilpisch K, Peterson BJ, Feldman DS, Abraham WT.  Cardiac resynchronization therapy may benefit patients with left ventricular ejection fraction >35%: a PROSPECT trial substudy.  Eur J Heart Fail 2010;12:581-587.